Plus   Neg

Xerox Launches Tender Offer To Buy HP Shares; HP To Review Xerox Offer

Xerox Holdings Corp (XRX) announced that it launched tender offer to acquire all outstanding shares of HP Inc. (HPQ) for $24.00 per share, comprising $18.40 in cash and 0.149 Xerox shares for each HP share. The offer and withdrawal rights are scheduled to expire at 5:00 p.m. New York City Time on April 21, 2020, unless the offer is extended.

HP Inc. confirmed that Xerox has commenced exchange offer and shareholders are advised to take no action at this time pending the Board's review and evaluation of the Offer. The HP Board will carefully review and believes is in the best interests of the Company and all HP shareholders. HP intends to advise shareholders of the Board's position regarding the Offer within ten business days.

"Our proposal offers progress over entrenchment," said John Visentin, vice chairman and chief executive officer of Xerox. "HP shareholders will receive $27 billion in immediate, upfront cash while retaining significant, long-term upside through equity ownership in a combined company with greater free cash flow to invest in growth and return to shareholders."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT